Illumina™ Veriseq™ NIPT Test is a new generation, non-invasive, prenatal test (NIPT – Non-Invasive Prenatal Test). It is a screening test that provides answers about the possible presence of fetal chromosomal abnormalities such as Down Syndrome or other common anomalies.
It is fast and risk-free for the mother and child because it is not invasive. By analyzing fetal DNA fragments released from placental trophoblasts and circulating freely in maternal blood, it is possible to identify which subjects are at risk and for which a further investigation.
Illumina™ Veriseq™ NIPT Test CE-IVD CERTIFIED (In Vitro Diagnostics) FOR TRISOMIES 21, 18 AND 13 AND CHROMOSOME ANEUPLOIDIES.
What type of sample is collected from pregnant women for Illumina™ Veriseq™ NIPT Test?
Illumina™ Veriseq™ NIPT Test analyzes the child’s DNA fragments released by placental trophoblasts and circulating freely in maternal blood.
The test consists of taking a simple blood sample from the mother bloom in Streak Tube. It has no side effects, is not invasive and does not pose any risk to the mother or child.
How Long will it take to get results for NIPT Test?
The procedure is simple and the result is obtained in only 7 to 10 working days from receipt of the blood sample at the laboratory.
DNA labs India keeps offering you assistance after issuing the report: in case of positive results, our geneticists will be available for consultation and it will be possible to test amniocentesis or chorionic villus sampling free of charge at affiliated centres.
Who is suggested to get the NIPT Test?
Illumina™ Veriseq™ is ideal for all pregnant women as it avoids the risks associated with invasive diagnostic tests. It can be performed from the 10th week of pregnancy onwards.
NIPT can also be performed in the cases of:
- twin pregnancies;
- egg donation pregnancies;
There are conditions for which a NIPT DNA screening test is particularly recommended:
- when the mother is over the age of 35;
- a POSITIVE result for the first or second quarter screening (Bi/Tri Test);
- pregnant women at risk of miscarrying;
- abnormalities in the child detected via ultrasound;
- family history pointing towards the risk of chromosomal
What is the cost of NIPT Illumina Veriseq Test?
The cost of NIPT Illumina Veriseq Test is 13000/- and the results are accurate up to 99.99%.
How to book the NIPT Illumina Veriseq Test?
You can either book your test by clicking on “book test” to book your NIPT Illumina Test and you will be provided home collection free of cost.
What Does Veriseq™ NIPT Test analyze?
Veriseq™ NIPT Test is the prenatal screening test able to detect trisomies 21, 18 and 13, chromosome aneuploidies.
Some genetic diseases are hereditary, others, such as Down Syndrome, can occur in any pregnancy. The risk of chromosomal abnormalities is greater as gestational age increases, rising drastically after the age of 35.
Veriseq™ NIPT Test ascertains the possible risk of trisomies – namely, conditions that occur when a subject presents an extra chromosome as compared to the habitual chromosome pair – as in the case of Down Syndrome, Edwards Syndrome and Patau Syndrome.
Down Syndrome (trisomy 21): this is the most frequent trisomy at birth and is caused by the presence of an extra copy of chromosome 21. It is associated with severe or moderate mental disabilities. It can also cause problems that affect the digestive and cardiovascular systems. NIPT Test detects Down syndrome with an accuracy of 99.99%
Edwards syndrome (trisomy 18): this is caused by the presence of an extra copy of chromosome 18 and is associated with severe malformations with a high risk of miscarriage and reduced life expectancy. NIPT Test detects Edwards syndrome with an accuracy of 99.99%
Patau Syndrome (trisomy 13): this is caused by the presence of an extra copy of chromosome 13 and is associated with a high risk of miscarriage. Children born with Patau Syndrome usually present severe congenital heart defects and other malformations and are unlikely to survive beyond the first year of life. NIPT Test detects Patau syndrome with an accuracy of 99.99%
As for sexual aneuploidies, 1 in 400 men and 1 in 650 women suffer from sex chromosome aneuploidies. The consequences of these types of abnormalities are generally less severe than the previously listed trisomies.
Turner syndrome (45, X0): due to the presence of only one X chromosome in women, with a frequency of approximately 1 in 3,000. Affected subjects have a female phenotype, but in 85-90% of cases, due to premature ovarian failure, they do not develop or only partially develop secondary sexual characteristics and are infertile or experience early menopause. Furthermore, these subjects may present with cardiac defects, renal abnormalities and short stature. Intelligence is usually normal but learning disorders, psychomotor retardation and behavioural disorders may be present.
Klinefelter Syndrome (47, XXY): Klinefelter Syndrome is a condition characterized by the presence of an extra X sexual chromosome in male subjects. Affected subjects have low testosterone levels, and if not treated early during puberty, may suffer from hypogonadism and infertility. There is an increased risk of language delay and learning disability.
Chromosome X trisomy (47, XXX): due to the presence of an extra X chromosome in females. This is the most common female chromosome abnormality, occurring in approximately 1 in 1,000 female births. It does not involve unusual phenotype characteristics. Proportionate tall stature is often reported. Pubertal development is normal, but in a third of cases reduced fertility, dysmenorrhoea and early menopause may be observed. In two-thirds of cases, a delay in psychomotor development may be observed.
Jacobs Syndrome or Y disomy (47, XYY): Double Y syndrome has an incidence of approximately 1 in 1,000 male births. Most men are tall and show normal sexual development as well as usually preserved fertility. Intellectual development is usually normal, however, delays in language, learning disability and muscle hypotonia may be observed.